Key Highlights

  • Top-line Revenue advanced 52.9% to USD 759.3 million this quarter from USD 496.7 million, and nine-month revenue hit USD 2,251.7 million, a 56.7% increase.
  • Net income swung to USD 6.4 million from a USD 24.4 million loss, and adjusted EBITDA, a non-GAAP figure, rose to USD 16.1 million from USD 2.1 million.
  • Medicare Advantage enrollment reached 158,907 on September 30, 2026, against 109,226, while the benefits expense ratio improved 240 basis points to 91.1%.
  • Guidance for full-year revenue now runs USD 2.97 billion to USD 3.00 billion and GAAP Net Income USD 25 million to USD 35 million, with both ranges tightened.

Enrollment Gains Carry Revenue and Earnings Back Into Profit

The company reported third-quarter results on November 4, 2026. Insurance revenue rose 56.3% to USD 748.8 million, and net medical claims grew 52.5% to USD 654.1 million, pulling the benefits expense ratio down to 91.1% from 93.5%. Gross Profit on a non-GAAP basis increased 77.3% to USD 129.8 million. Nine-month GAAP net income reached USD 61.8 million, reversing a USD 36.2 million loss. Membership was up 45% at quarter end, 46.3% on an average basis and 48.8% over nine months, while a subtitle in the release cites 49%, consistent with the nine-month average.

Administrative Costs, Star Ratings and Capital

Adjusted SG&A, also non-GAAP, grew 60.1% to USD 113.8 million, equal to 15.0% of revenue versus 14.3%. Clover uses its Clover Assistant software to help physicians care for Medicare Advantage patients, and its flagship PPO, which covers about 98% of members, earned a 5 Star rating for Payment Year 2028. Cash, cash equivalents and investments came to USD 512.6 million, up from USD 395.9 million. Management said 2027 annual enrollment is tracking well, though no figures were offered, and it plans a conference presentation on November 9, 2026.

Narrowed Guidance Higher and the Margin Exposure Beneath It

For 2026 Clover now projects average Medicare Advantage membership of 157,000 to 158,000, consolidated gross profit of USD 540 million to USD 555 million and adjusted EBITDA of USD 75 million to USD 85 million. Earlier ranges were USD 525 million to USD 555 million for gross profit and USD 70 million to USD 85 million for adjusted EBITDA, so the lower bounds have risen. The CFO expects the company's first full year of GAAP profit. The thin spread is the main risk: a benefits expense ratio near 91% leaves little room for medical cost swings, and Medicare Advantage rating and payment rules remain a dependency.

Where Things Stand

Top-line growth is evident, but the profit path is less clear. Clover Health Investments (NASDAQ:CLOV) converted 52.9% revenue growth into USD 6.4 million of net income and USD 16.1 million of adjusted EBITDA, while the benefits expense ratio improved 240 basis points to 91.1%. That ratio leaves limited headroom, and adjusted SG&A is rising faster than sales. Full-year GAAP net income guidance of USD 25 million to USD 35 million trails the USD 61.8 million earned in nine months, implying a fourth-quarter loss of roughly USD 27 million to USD 37 million (calculated), a gap the release does not explain. Investors should watch the 2027 enrollment figures once they are released, since the release gives no numbers yet.